Clinical use of phosphodiesterase-5 (PDE5) inhibitors is limited by several side effects due
to weak isoform selectivity. Herein, a unique allosteric pocket of PDE5 is identified by …

We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl
cinnoline 1 using a combination of computational modeling and structural–activity …

Abstract Phosphodiesterase-4 (PDE4) and PDE5 responsible for the hydrolysis of
intracellular cAMP and cGMP, respectively, are promising targets for therapeutic intervention …

Abstract Phosphodiesterase 5 (PDE5) is one of the most well-studied phosphodiesterases
(PDEs) that specifically targets cGMP typically generated by nitric oxide (NO)-mediated …

Cyclic nucleotide phosphodiesterases 4 (PDE4) are a family of enzymes which specifically
promote the hydrolysis and degradation of cAMP. The inhibition of PDE4 enzymes has been …

To validate the hypothesis that Tyr748 is a crucial residue to aid the discovery of highly
selective phosphodiesterase 8A (PDE8A) inhibitors, we identified a series of 2 …

The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating levels of
the second messenger cAMP. Consequently, PDE4 inhibitors have been investigated as a …

Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the
nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and …

The discovery of novel, potent and selective PDE5 inhibitors - ScienceDirect Skip to main
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …

PDE9 inhibitors have been studied as therapeutics for treatment of cardiovascular diseases,
diabetes, and neurodegenerative disorders. To illustrate the inhibitor selectivity, the crystal …